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Tamoxifen is an anti-oestrogenic drug widely used for
Numerous studies have established an increased incidence of adjuvant therapy of breast cancer. Its use has caused an endometrial cancer among women taking tamoxifen (7,8). increased incidence of endometrial cancer and it is also a Recent results confirm not only an increased incidence of potent carcinogen in rat liver. Since the demonstration that endometrial cancer (relative risk up to 7 compared with nontamoxifen forms covalent DNA adducts in rat liver, many users), but also increased mortality from the disease (9), investigations of its mechanism of carcinogenic action have implying that the tamoxifen-induced neoplasms are in some focused on the examination of human and animal tissues way pathologically different from those not associated with for the presence of tamoxifen-DNA adducts, the identificause of the drug. Endometrial thickening is evident in a much tion of their structures and the determination of the larger percentage of women (10). While the benefits of metabolic pathways that lead to their formation. This article tamoxifen to breast cancer patients far outweigh the risks, reviews the current evidence for genotoxic mechanisms for findings such as these question the widespread use of tamoxifen tamoxifen carcinogenicity, and discusses some inconsistenby healthy women to prevent breast cancer. cies in the data.
In rats, tamoxifen is a potent hepatocarcinogen in both males and females (11). Also, when administered to neonatal rats, uterine adenocarcinomas were induced along with a lower Use of tamoxifen frequency of squamous cell carcinomas of the vagina/cervix The drug tamoxifen, (Z)-1-{4-[2-(dimethylamino)ethoxy]-(12). In mice, however, liver is not the target tissue for phenyl}-1,2-diphenyl-1-butene, is a non-steroidal anti-oestrocarcinogenesis. Instead, tumours of the testis are induced in gen for the treatment of breast cancer, the most common form males, and of the ovaries in females (13); tumours also develop of cancer in women world-wide. By virtue of its proven in the uterus when tamoxifen is administered neonatally (14) efficacy in extending remission and survival from primary but not when fed in the diet from 8 weeks old for 2 years breast cancer and in reducing the incidence of contralateral (15) . When administered transplacentally to mice, tamoxifen breast cancer in women who have already had a breast causes a high incidence of hyperplasia in the reproductive tumour (1), it is now the world's most widely used cancer tract, and a lower incidence of tumours, in offspring (16) . chemotherapeutic agent. It has undergone trials in several
Testing of tamoxifen for carcinogenic activity in other species countries to determine whether its administration to healthy has not been reported. women at high risk of breast cancer can reduce the incidence While it might initially have been thought, or assumed, of malignancy. Results have been mixed, with a US trial that the hepatocarcinogenicity of tamoxifen in rats was the showing significant benefits of prophylactic tamoxifen in consequence of its oestrogenic activity, this view was chalreducing breast cancer incidence in healthy high-risk women lenged when it became apparent that the tumours induced (2), but with UK (3) and Italian (4) trials showing no such were not benign adenomas, but highly malignant carcinomas. benefit (yet). Other pharmacological properties of tamoxifen, Furthermore, tumours were induced in up to 80% of animals including beneficial effects on bone density and lipid profiles, of both sexes (11). Other studies on female rats only have also have led to the development of new selective (o)estrogen demonstrated the potency of tamoxifen as a liver carcinogen receptor modulators (SERMs) that may have the dual benefit (17-19). When it was found that tamoxifen gave rise to DNA of preventing osteoporosis and breast cancer; two such drugs adducts in rat liver (20, 21) , it was apparent that the compound of current interest are the tamoxifen analogue toremifene (5) could undergo metabolic activation to an electrophilic species and the benzothiophene raloxifene (6).
that binds covalently to cellular macromolecules and that could With the widespread therapeutic and emerging prophylactic therefore be carcinogenic by a genotoxic mechanism (22) (23) (24) . use of tamoxifen, there has been much discussion about sideIt should be noted that in all standard short-term tests for effects of the drug, particularly its carcinogenicity. It is the carcinogenicity, based on detecting the consequences of DNA intention of this article to summarize what is known about damage, tamoxifen gave negative results (8,13). However, as the mechanism of tamoxifen carcinogenicity in animals and will be mentioned later, a key metabolite of tamoxifen is humans, and to speculate on the extent to which extrapolation mutagenic when suitable conditions for its metabolism are from one species to another will be reliable in predicting longmet. A number of other experimental observations are compatible with genotoxic activity: tamoxifen induces micronuclei by tamoxifen were found to contain mutations in the p53 gene oxidative metabolism at this position was predicted to generate (32). While no single piece of evidence would be sufficient to a resonance-stabilized carbocation capable of electrophilic designate it a genotoxic carcinogen, taken together with its attack on nucleophilic centres in DNA, leading to the formation DNA adduct forming ability these data can be construed as of stable covalent DNA adducts. indicating that tamoxifen exhibits the properties of a genotoxin, Ensuing experimental studies by a number of investigators at least in some circumstances.
have, to a large extent, borne out this hypothesis. When substituted with deuterium at the α-position, the DNA adduct Mechanism in rats forming ability of tamoxifen in rat liver in vivo and in rat hepatocytes in vitro is significantly reduced (26,40). The extent A powerful means of determining the pathways of activation of the reduction, Ͼ2-fold, is compatible with the 2-3-fold of a carcinogen is to characterize and quantify the DNA slower rate of oxidative metabolism at the α-position when it adducts it forms, and to determine what factors either enhance is deuterated, as demonstrated in a study using rat liver or inhibit DNA adduct formation. Much has been learned microsomal fractions (37) . Deuterium substitution at the β-about the metabolic activation of tamoxifen using this approach, position does not reduce the DNA binding activity of tamoxifen and the method of detection most commonly used has been (40) . These results indicate the importance of metabolism at the highly sensitive 32 P-post labelling method. DNA adduct the α-position in the metabolic activation of tamoxifen. Indeed, formation has also been demonstrated by mass spectrometry when the DNA binding potential of α-hydroxytamoxifen, the (33), accelerator mass spectrometry (AMS) (34) and, using predicted intermediate, was determined in rat hepatocytes antibodies raised against tamoxifen-adducted DNA, by compet-(41,42) and, subsequently, in rat liver in vivo (40, 43) , it was itive dissociation-enhanced lanthanide fluoroimmunoassay found to bind to DNA at up to 50-fold higher levels than an (DELFIA) and chemiluminescence immunoassay (CIA) (35).
equal concentration or dose of tamoxifen. As the adduct The metabolism of tamoxifen has been widely studied and patterns of the two compounds were indistinguishable, this is shows that several positions of the molecule are sites for further strong evidence that tamoxifen-DNA binding is medibiotransformation (36, 37) (Figure 1 ). In human metabolism ated through α-hydroxylation. studies, many metabolites are isolated as glucuronyl conjugates Interestingly, the Potter hypothesis (39) predicted that if (38) . The principal sites of Phase I metabolism are the nitrogen α-hydroxylation occurred in combination with 4-hydroxyatom of the side chain (N-oxidation and demethylation) and lation, a more stable carbocation would be generated than if the 4-position (hydroxylation). Other positions also subject to α-hydroxylation alone occurred. Indeed, comparison of the metabolism include the α-position of the ethyl side chain reactivity of α-hydroxytamoxifen and α,4-dihydroxytamoxifen (hydroxylation). Although it is a relatively minor site for shows that the latter reacts more extensively with DNA (44,45). metabolism, it was proposed on theoretical grounds that the α-position is the primary site of metabolic activation (39), as A number of postulated reactive intermediates derived from 4-hydroxytamoxifen, including the quinone methide (39), also dependence on sulfate and on sulphotransferase activity suggests that a pathway involving α-hydroxylation dominates react readily with DNA to give stable adducts (45, 46) . This suggests that 4-hydroxytamoxifen, a major metabolite of over other potential pathways of activation in liver cells. With improvements in the resolution of tamoxifen-DNA tamoxifen, would give rise to DNA adducts in cells. In one study adduct formation by 4-hydroxytamoxifen in rats has adducts by HPLC, it became apparent that the pattern of adducts was more complex than could be accounted for simply been reported (47) , but in subsequent studies adduct formation by this metabolite was not detectable in rat hepatocytes (45) by the activation of tamoxifen to a carbocation of tamoxifen itself. It has now been shown that a parallel adduct formation or in rat liver in vivo (45, 48) , even though the metabolite can be enzymatically activated to products that bind to DNA pathway involving N-demethylation, in addition to α-hydroxylation, occurs (Figure 2 ) (33, 40, 59, 60) . Examination (47,49) in cell-free or sub-cellular systems. Furthermore, 4-hydroxytamoxifen activation by the peroxidase/H 2 O 2 system of the adduct forming potential of a number of metabolites has demonstrated that N-demethylation can either precede or in vitro gave a more polar DNA adduct seen only at trace levels in liver DNA from tamoxifen-treated rats (50). In follow α-hydroxylation in the activation pathway, with N,Ndidemethylation, again with α-hydroxylation, constituting a another study, administration of 4-hydroxytamoxifen to rats for 14 days gave rise to unspecified, but apparently low, levels minor additional pathway (40, 59 ). Another accompanying pathway that has been considered of DNA adducts in liver that were chromatographically distinct from those formed at much higher levels by tamoxifen itself is N-oxidation. The available evidence on tamoxifen N-oxide or metabolites containing the N-oxide function suggests that (51). Thus tamoxifen activation in rat liver does not proceed via 4-hydroxylation. Presumably an efficient detoxifying mechthey are not involved to any great extent in in vivo DNA adduct formation in rats. Tamoxifen N-oxide is a major anism, probably involving Phase II conjugation at the 4-position, is operating in intact cells and it therefore comes metabolite when tamoxifen is incubated with rat liver microsomes (36) and although tamoxifen-N-oxide and α-hydroxytaas no surprise that 4-hydroxytamoxifen is not carcinogenic when applied topically to rat skin (52). [The rationale for this moxifen-N-oxide form adducts in rat liver and in hepatocytes, these are chromatographically indistinguishable from those seemingly bizarre experiment is that topical application of 4-hydroxytamoxifen to the breast has been proposed as a formed by tamoxifen and α-hydroxytamoxifen, which in turn co-chromatograph with standards not possessing an N-oxide therapy for breast cancer (53)]. The experience with 4-hydroxytamoxifen should serve as a powerful reminder to all investigfunction (40) . Thus it would appear that loss of the N-oxide occurs prior to further metabolism to activated species, or ators that it is insufficient to demonstrate the DNA binding of a metabolite or putative metabolite in a cell-free or sub-cellular prior to DNA binding. The facile reduction of tamoxifen Noxide back to tamoxifen by rat and human liver microsomes system (where the balance of activation and detoxification pathways may be substantially altered) in order to give credence suggests that the N-oxide may serve as a storage form for tamoxifen in vivo (61), i.e. N-oxidation appears to be reversible to a particular theory of metabolic activation. It is necessary also to demonstrate that this binding occurs in whole cells in the rat. There are several as-yet-unidentified minor tamoxifen-derived DNA adducts detected in rat liver and it is in vitro and/or in mammalian tissues in vivo.
Although α-hydroxytamoxifen exhibits weak DNA binding conceivable that some of these are derived from tamoxifen N-oxide. activity at physiological pH (and increasing reactivity at progressively acidic pH) (54), it is clear from its high DNA α-Hydroxytamoxifen has a chiral carbon atom, and therefore exists as two enantiomers. These have recently been resolved, binding activity in cells that it undergoes Phase II metabolism to a more reactive intermediate. Tamoxifen bears structural their absolute configurations assigned and their potential to form DNA adducts in rat hepatocytes compared: the R-(ϩ)-features analogous to those of the naturally occurring carcinogens safrole and estragole, whose pathway of metabolic activaisomer has a much higher binding activity than the S-(-)-isomer [Osborne,M.R., Hewer,A. and Phillips,D.H. (2001), in tion also involves hydroxylation at a carbon atom adjacent to a conjugated allylic position, and which form DNA adducts preparation]. Both enantiomers will give rise to the same carbocation, from which both epimers of each adduct can arise in which the exocyclic amino group of guanine and adenine are the principal sites of modification in DNA (55) . Using α-as chirality at the α-position returns. Thus, for one enantiomer to be more biologically active, it can be assumed that it is a acetoxytamoxifen or the sulfate ester of α-hydroxytamoxifen as model electrophiles, the adducts formed by tamoxifen were better substrate for activation and/or a poorer substrate for detoxification enzymes than its enantiomeric partner. identified as also consisting of guanine and adenine moieties modified at the exocyclic amino groups (54, 56, 57) . Rotation
Returning to the issue of the Phase II activation step of α-hydroxytamoxifen (with or without accompanying N-oxidation of the carbocation about the central bond of the molecule can occur, leading to the formation of both cis and trans adducts.
and N-demethylation), the role of hydroxysteroid sulphotransferase, implicated by the sulfate-dependent and DHEASOnce formed, cis and trans adducts are stable and do not interconvert. Phase II activation of the proximate carcinogen inhibited DNA binding of the metabolite and parent compound in hepatocytes (58) , is reinforced by direct studies with 1'-hydroxysafrole is mediated by sulphotransferase and there is now good evidence that tamoxifen activation also occurs the enzyme. Firstly, recombinant rat liver hydroxysteroid sulphotransferase rHSTa catalyses the binding of α-hydroxytavia sulfate ester formation from α-hydroxytamoxifen. When rat hepatocytes were incubated with tamoxifen in sulfate-free moxifen to DNA (62) . Also, in Salmonella typhimurium TA1538 and Chinese hamster V79 cells genetically engineered media, DNA adduct formation was significantly reduced, but was restored by the addition of sulfate salts (58) . Likewise, to express rHSTa, α-hydroxytamoxifen is mutagenic and forms DNA adducts (63, 64) ; this is the only example of in vitro co-incubation (in normal media) with dehydroisoandrosterone-3-sulphate (DHEAS), a hydroxysteroid sulphotransferase mutagenicity of a tamoxifen metabolite. There are some, including an anonymous reviewer of one inhibitor, reduced DNA adduct formation (58) . The fact that tamoxifen and α-hydroxytamoxifen showed entirely similar of this author's grant applications, who have maintained that the carcinogenicity of tamoxifen in rat liver has nothing to do male (65), yet tamoxifen is equipotent in inducing liver tumours in both sexes (11). Curiously, all the early work on adduct with DNA adduct formation. Indeed, the proposed pathway of activation by hydroxysteroid sulphotransferase rHSTa creates formation had been carried out in only female rats and hepatocytes. When we compared adduct formation in male a paradox: this enzyme, a member of the SULT2A subfamily, is expressed in female rat liver but barely detectable in the and female hepatocytes, we found that it was much lower (11-fold) in the male cells (66) . Furthermore, treatment of rats hydroxyguanine formation in DNA in rat liver microsomal incubations (76) , but the extent to which this may occur in vivo with a single oral dose of tamoxifen resulted in 6-fold lower adduct levels in the liver of males than in females. However, is not known. Conversely, there is extensive documentation of the antioxidant properties of tamoxifen (and 4-hydroxytamoxwhen tamoxifen was administered daily, thereby mimicking the protocol of the animal carcinogenicity experiments (11), ifen) in a number of experimental systems (5); these properties may contribute to the chemopreventive action of the drug. It adduct levels in males were, by 14 days, similar to the levels in females. The explanation is that in the male rat liver has been shown that peroxidases can activate tamoxifen and 4-hydroxytamoxifen to intermediates that react covalently with tamoxifen administration induces specifically rHSTa, the sulphotransferase isoform that activates α-hydroxytamoxifen (66) DNA in vitro (47, 77) , but the extent to which this pathway occurs in vivo is unknown, as is the possibility that other (nonsuch that tamoxifen-DNA adduct formation is similar in both sexes with prolonged exposure, thereby rendering males tamoxifen) reactive species generated by this pathway could cause DNA damage (78). It has been suggested (78) that equally susceptible to liver tumour induction as females. Thus, the close correlation between DNA adduct formation, tamoxifen-induced micronucleus formation in MCL-5 cells (25) and aneuploidy and chromosome exchanges in rat hepatosulphotransferase activity and tamoxifen carcinogenicity in the liver is maintained.
cytes (29) could be the result of oxidative stress rather than 'direct' genotoxicity, and indeed, tamoxifen-DNA adducts With increasing duration of exposure to tamoxifen, there is a change in the relative amounts of the tamoxifen and Nwere not detected in MCL-5 cells exposed to tamoxifen under conditions that induced micronucleus formation (A.Hewer, desmethyltamoxifen adducts: after 1 day the former outnumber the latter by a factor of 2.3, but after 14 days the latter are F.L.Martin and D.H.Phillips, unpublished results). predominant by a factor of 1.4 (66) and are also the more abundant adducts after 18 months of chronic exposure (51).
Mechanism in mice This is possibly the result of different rates of DNA repair but a more likely explanation is induction of N-demethylation by Tamoxifen forms DNA adducts in the liver of mice, but at lower levels than in the rat. Short-term treatment of mice with one or more CYP isozymes (67, 68) .
If further proof of the biological significance of tamoxifentamoxifen resulted in adducts at a level 30-40% of that induced by comparable treatment of rats (21). In primary cultures of DNA adducts is needed, it is provided by the demonstration that the adducts are miscoding lesions in vitro (69) and mouse hepatocytes, adduct formation by tamoxifen was 6-fold lower than in rat hepatocytes (42) . are subject to nucleotide excision repair (70) . They induce predominantly GC-TA transversions when modified DNA is Adducts do not accumulate in mice chronically exposed to tamoxifen (79) . Continuous feeding led to the detection of replicated in simian kidney (COS-7) cells (71) . This is also the predominant in vivo mutation occurring in the livers of adducts after 3 months, but not after 2 years of exposure. This suggests the slow induction of a detoxification pathway. This transgenic rats administered tamoxifen (31, 72) .
Interestingly, in these experiments with transgenic rats is in contrast to the situation in rat liver where adducts accumulate to a great extent (19). Earlier studies in which (31, 72) , only in the liver were mutations detected. 32 P-Postlabelling analysis of DNA from other tissues provides scant mice were treated with tamoxifen intraperitoneally showed the existence of a major pathway, apparently involving activation evidence for tamoxifen-DNA adduct formation. Most tissues studied appear to be devoid of adducts (21) (A.Hewer and via α-hydroxylation, and a minor but inducible pathway proceeding via 4-hydroxytamoxifen (80-82). D.H.Phillips, unpublished results). In one study an adduct was reported to be formed in the uterus (49), but our own attempts
In a recent study of tamoxifen-DNA adducts formed in mouse liver following administration of the compound by to replicate this finding using the identical treatment protocol did not result in the detection of adducts in this tissue (A.Hewer gavage, minor adducts (~7% of total) were attributed to binding at the α-position of tamoxifen N-oxide (83) and supporting and D.H.Phillips, unpublished results). Several other studies have also found no evidence of adduct formation in rat uterus studies on the reactivity and adduct formation by α-acetoxytamoxifen N-oxide have been carried out (84). The major (12,43,48,73).
Nevertheless, another technique for adduct determination, adducts in mouse liver were reported to derive from α-hydroxytamoxifen (83), and it remains to be determined accelerator mass spectrometry (AMS) gives somewhat different results on this issue. This method is much the most sensitive whether N-desmethyltamoxifen is also a precursor of DNA adducts in this tissue. method for detecting DNA binding (74), but does not give structural information on the nature of the binding. Following
It has long been a central tenet of chemical carcinogenesis that DNA adduct formation (or DNA damage) is a necessary, administration of 14 C-tamoxifen to rats, the radioisotope was found to be associated with the DNA isolated from several but not sufficient, event/stage in the mechanism of action of a genotoxic carcinogen. This is exemplified by the formation tissues (34), at levels that should have been detectable by 32 P-post labelling, assuming the radioisotope is in the form of of tamoxifen-DNA adducts in mouse liver, which does not give rise to liver tumours. These adducts do not appear to covalently bound tamoxifen. Therefore, at present there remain uncertainties as to the nature of this observed binding in accumulate in mouse liver whereas they do in rat liver, where tumours arise at high frequency. It will be interesting to see extrahepatic tissues (a previously unrecognized form of DNA binding by tamoxifen moieties that is not detectable by whether tamoxifen can induce liver tumours (or any tumours, for that matter) in mice deficient in DNA repair, such as XP 32 P-post labelling?), and questions about its biological significance, given the lack of tamoxifen-induced mutations in all knockout mice. However, it is also the case that tamoxifen induces cell proliferation in rat liver providing a tumour tissues except the liver (31, 72, 75) .
Could tamoxifen and/or its metabolites also be giving rise promoting influence (19), but not in mouse liver (79) . While these differences in adduct persistence and cell proliferation to DNA damage indirectly, via oxidative and free radical pathways? Both tamoxifen and 4-hydroxytamoxifen induce 8-go some way to explain why the liver of one species but not the other is susceptible, the reasons for the interspecies rat microsomes sulfate ester formation predominates over glucuronidation (93) . This provides an explanation for the differences in response are not clear.
The induction of uterine adenocarcinomas in mice following paucity of DNA adduct formation by tamoxifen and α-hydroxytamoxifen in human hepatocytes in vitro (42) and the neonatal treatment (14), but not following administration to adult animals (15), suggests a mechanism involving hormonal apparent lack of adduct formation in the liver of women taking tamoxifen (90). perturbation of the developing organ. There do not appear to have been any attempts to detect tamoxifen-DNA adducts in In summary, α-hydroxylation is more prevalent in rodent liver cells than in human cells, as is sulfate ester formation the reproductive tract of female mice. from this metabolite. At the same time, the alternative pathway of glucuronylation, leading to a detoxified conjugate, is more Mechanism in humans prevalent in human systems than in rodent ones. The situation regarding tamoxifen-DNA adducts in human Metabolism of tamoxifen in humans appears to be qualitatively similar to metabolism in rodents (38) and it is noteworthy that endometrium is much less clear. Initially we did not find evidence for DNA adduct formation in endometrial samples α-hydroxytamoxifen is a detectable metabolite in the plasma of women on long-term tamoxifen therapy (85). Also, steadyfrom 18 women receiving tamoxifen therapy, with an estimated detection limit of 4 adducts/10 10 nucleotides (94). This lack state serum levels of N-desmethyltamoxifen are higher than those of tamoxifen itself in patients on long-term tamoxifen of adduct formation in vivo was mirrored by the lack of tamoxifen-DNA adduct formation in short-term organ cultures therapy (86).
Although there have been some case reports of acute liver of endometrial tissue incubated with high concentrations (500 µM) of tamoxifen (94). α-Hydroxytamoxifen gave rise to low toxicity of tamoxifen (87), there have been no findings of increased liver cancer among tamoxifen-treated women levels of adducts only at concentrations several orders of magnitude higher than would occur in vivo, analogous to the (88, 89) , albeit with relatively short periods of follow-up given the potentially long latent period for induction of carcinomas situation in primary cultures of human hepatocytes. These results are in contrast to a subsequent study in which in humans. A small 32 P-post labelling study of liver DNA from seven individuals taking tamoxifen revealed moderate tamoxifen-DNA adducts were reported to be present in the endometrial tissue of 4/6 treated patients at levels of 2.7/10 9 levels of DNA adducts but was not able to distinguish the presence of any resulting from tamoxifen binding, and the nucleotides, but were undetectable in 5 controls (95) . The evidence for DNA binding in this study was the appearance total levels were not higher than those found in the liver DNA of seven control subjects (90). A single liver sample (postof a minor radioactive peak on HPLC seen against a very high background, and the validity of this claim has been questioned mortem) from a tamoxifen-treated patient analysed in this author's laboratory did not reveal the presence of any tamox-(96). Subsequently, we analysed DNA from a further 34 endometrial samples using the chromatographic conditions of ifen-derived adducts (unpublished result).
In experiments with primary cultures of human hepatocytes, Hemminki and colleagues (95) . Under these conditions we also detected a minor chromatographic peak co-eluting with tamoxifen did not form adducts, and DNA binding by α-hydroxytamoxifen was Ͼ100-fold lower than in female rat the major rat liver tamoxifen-DNA adduct in some of the samples, but it was found to be present not only in those from hepatocytes (42) ; this low level of binding was possibly the result of chemical reaction of the compound without metabolic 7/14 tamoxifen-treated women, but also in samples from 3/6 toremifene-treated women and from 5/14 untreated controls activation. Concentrations of α-hydroxytamoxifen detected in the media of the human hepatocytes treated with tamoxifen (97). The detection limit for these analyses was estimated at 1 adduct/10 9 nucleotides. We concluded that the peak is either was also significantly lower (~50-fold) than in the media of rat hepatocytes (42) . While these results reveal marked an artefact of the post labelling procedure or a background (endogenous) adduct that is not derived from tamoxifen. A interspecies differences, they do not exclude the possibility that prolonged exposure to tamoxifen may result in induction report of the presence of tamoxifen-DNA adducts in white blood cells of patients, based on similar identification criteria of a human liver enzyme that activates the compound, analogous to the situation in male rats (66) . (98), was similarly not reproduced in our own studies (99,100). Using improved 32 P-post labelling and HPLC procedures that Does the proposed mechanism of activation in rat liver indicate a reason for the lack of adducts (and carcinogenicity) result in considerable reductions in background radioactivity, Shibutani et al. (101, 102) have recently reported the detection in human liver? There is evidence that α-hydroxytamoxifen is a poorer substrate for sulphotransferase in humans than in rats.
of tamoxifen-DNA adducts in endometrial tissue from 8/16 patients, and their absence from all of 15 controls. The adducts Sulfate ester formation (leading to adduct formation) from α-hydroxytamoxifen by the purified recombinant enzymes is at were identified by virtue of their co-chromatography with synthetic tamoxifen adducts, and were estimated to be present least 3-fold more efficient with the rat rHSTa isozyme than with the human isoform (91), but the difference is considerably at levels in the range 0.2-18.0 adducts/10 8 nucleotides. The detection limit was reported to be 2.5 adducts/10 10 nucleotides. greater when the enzymes are expressed in bacterial or mammalian cells: α-hydroxytamoxifen was mutagenic and formed These adduct levels are clearly much higher than those previously estimated. However, what is highly unusual about detectable levels of DNA adducts in the cells expressing the rat rHSTa enzyme, but not in those expressing any of the these results is that the ratio of cis and trans tamoxifen-DNA adducts differs widely between individuals, with some samples known human sulphotransferases, indicating at least a 20-fold difference in affinity for the substrate (64) . α-Hydroxytamoxcontaining predominantly the trans adducts but others containing only the cis adducts. This is not what would be ifen can also undergo glucuronidation (92), which is likely to be a detoxification (inactivation) pathway. In incubations of expected from the animal experiments, or from the pattern of adducts formed in the chemical reaction of reactive derivatives α-hydroxytamoxifen with human liver microsomal fractions glucuronidation predominates over sulphonation, while with of α-hydroxytamoxifen with DNA, where the products are DNA, toremifene gave rise to DNA adducts, although at levels lower than those formed by tamoxifen (103) . Also, toremifene induced micronucleus formation in MCL-5 cells (27, 28) but it was less active than tamoxifen and it did not show significant clastogenic activity in in vivo experiments (28) . These positive results with toremifene are, perhaps, due to the artificiality of some in vitro test systems and to an imbalance of the activation and detoxification systems operating in vivo or in 'normal' cells.
Insofar as it has been tested (i.e. exposure for up to 24 predominantly trans (54, 56, 91) . Logically, one would expect weeks), idoxifene (Figure 3) is not carcinogenic in rat liver to see a spectrum of mainly trans adduct peaks, including (104) . DNA adduct formation by idoxifene in rat liver in vivo ones derived from the N-desmethyltamoxifen metabolite as is two orders of magnitude lower than with tamoxifen (104), well as from tamoxifen itself, but this is not what has been while in experiments with rat hepatocytes it was found that reported (101,102). The chemistry of the interaction with DNA idoxifene does not form a detectable level of adducts and that of reactive intermediates of tamoxifen that give rise to a the putative metabolite α-hydroxyidoxifene is less active in carbocation at the α-position, and also the profile of adducts adduct formation than α-hydroxytamoxifen (105). Furtherformed when tamoxifen is activated in mammalian cells more, α-hydroxyidoxifene was less reactive than α-hydroxytain vitro or in vivo, clearly show that trans-tamoxifen adducts moxifen towards DNA at pH 5 (44), and α-acetoxyidoxifene predominate over cis-tamoxifen adducts. Therefore if tamoxwas less reactive than α-acetoxytamoxifen at pH 7 (105). ifen-DNA adducts are formed in human tissues it would be Droloxifene ( Figure 3 ) does not give rise to liver tumours expected that they would display the same cis:trans ratio as seen in rats (8) and it did not form detectable levels of DNA adducts under experimental conditions. Thus the apparent detection of in rat liver when investigated by 32 P-post-labelling (21). variable ratios of cis:trans adducts in human endometrium
Calculations of carbocation stability for a series of triphenylrequires an explanation. The suggestion that an as-yet-unidentiethylenes have shown that the intermediates of toremifene, fied polymorphism in a gene encoding a DNA repair enzyme idoxifene and 4-iodotamoxifen are significantly less stable could result in the preferential repair of one type of adduct in than that of tamoxifen, suggesting that they are less frequently some women and the other type in others (101) does not seem activated than tamoxifen in this manner (106). plausible if, as has been reported, the adducts are repaired by Thus tamoxifen stands alone in its class. The other theranucleotide excision repair (70), a mechanism capable of peutic anti-oestrogens do not cause tumours in rats, and form correcting a very wide spectrum of modifications to the DNA few, if any, DNA adducts in vivo. structure and sequence. Shibutani et al. (102) also suggest that our failure to detect Illumination or confusion? tamoxifen-DNA adducts in human endometrium may be due to insufficient sensitivity, but our own published methods have Tamoxifen-DNA adduct formation by the metabolic pathways a limit of sensitivity similar to theirs and have not yielded described herein, followed by cell proliferation, provides a evidence for tamoxifen-DNA adducts in our samples, and plausible mechanism for tumour formation in rat liver. The even when we replicated their post labelling procedures (101) mechanism can be defined as a genotoxic one. In mouse liver, adducts were not detected in our samples (A.Hewer and adduct formation is less persistent and there appears to be no D.H.Phillips, unpublished results). It is entirely conceivable concomitant stimulation of cell proliferation, so liver tumours that a low level of adducts could be present in human do not develop. Tamoxifen-DNA adducts are also formed in endometrium, given that α-hydroxytamoxifen has weak the liver of hamsters (20) and rhesus monkeys (107), in the intrinsic reactivity towards DNA (41,54), but this alone would latter case at levels at least an order of magnitude lower than not be likely to result in adduct levels in the endometrium as in rats. However, the drug has not yet been tested for high as those claimed (101, 102) . Using the ultrasensitive carcinogenicity in hamsters or monkeys. Human liver, in method of accelerator mass spectrometry (AMS), a single dose contrast, appears to be better protected against activation of of 14 C-tamoxifen to women resulted in as-yet-uncharacterized tamoxifen to DNA binding species. 'adduct' formation in the endometrium at up to 8 adducts/10 10 Thus tamoxifen presents something of a problem in the nucleotides (E.A.Martin, personal communication), but this arena of regulatory testing of pharmaceuticals for genetic level of binding is close to the limit of detection of the 32 Ptoxicity: negative in the battery of short-term tests, but demonpost labelling method.
strably genotoxic (and carcinogenic) in vivo. The failure of In summary, in vitro studies with human tissues or cells do the short-term tests to give positive results for tamoxifen is not show significant DNA adduct formation by tamoxifen probably explicable by the low rate of metabolism to α-in either hepatocytes or endometrium, and binding by α-hydroxytamoxifen and/or the low activity of sulphotransferases hydroxytamoxifen occurs only at high concentration, probably in the systems used. Only under special circumstances has a non-enzymically. In vivo, there is no evidence for adduct tamoxifen metabolite (α-hydroxytamoxifen) been shown to be formation in human liver, but differing results have been mutagenic in vitro. obtained with endometrium.
The nature of apparent DNA binding in extrahepatic rat tissues, detected by AMS but not, it seems, by 32 P-postAnalogues of tamoxifen labelling, clearly requires further investigation and characterization. The general lack of evidence by 32 P-post labelling Toremifene (Figure 3) is not carcinogenic in rat liver (17) and DNA adduct formation by toremifene in rat liver is either analysis for adducts in extrahepatic tissues is compatible with activation of tamoxifen at the α-position by hydroxysteroid undetectable (17) or extremely low (21,73). When incubated with rat or human microsomal fractions in the presence of sulphotransferase, since this is expressed almost exclusively in the liver. Unfortunately, because AMS measures isotope tamoxifen is a genotoxic carcinogen in one species (rat) and ratios it requires the use of 14 C-labelled drug for detection of a non-genotoxic carcinogen in another (human), this would DNA binding and thus cannot be used for the routine detection make it a highly unusual, if not unique, carcinogen. Since of tamoxifen-DNA adducts in human tissues.
tumours can be induced in rat uterus following neonatal Some studies report formation of tamoxifen-DNA adducts exposure, but adducts have not been reproducibly detected in in endometrium, others do not. However, the observed interinthis tissue, it may even be the case that tamoxifen is a genotoxic dividual variation in relative amounts of cis and trans adducts carcinogen in one tissue, and a non-genotoxic carcinogen in (101,102) is puzzling. No satisfactory explanation for this has another tissue of the same species. In the last decade some yet been advanced. We have not found unequivocal evidence very novel and interesting properties of tamoxifen carcinofor the presence of tamoxifen-DNA adducts in any of 54 genicity have been uncovered but the picture remains incomsamples of endometrial tissue from women taking the drug plete. Continued study of this important drug promises further (94,97) (and unpublished results). Since each human sample insight into its carcinogenic mechanism(s). Perhaps only then is unique, perhaps the question of whether adducts are truly can the title of this article be written as a statement, rather formed in human tissues can only be definitively answered by than as a question. an inter-laboratory comparison of analyses of coded tissue samples from exposed and control individuals, and when other Acknowledgements methods that take a different approach to DNA adduct detection and identification are brought to bear on the problem. Thus, Where these criteria are testable and not met, then the identi- carcinogenic to rat liver, and that do not form DNA adducts 12. Carthew,P., Edwards,R.E., Nolan,B.M., Martin,E.A., Heydon,R.T., therein, would be predicted to be safer alternatives to tamoxifen. genotoxic carcinogen? If it turns out to be the case that
